KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Depreciation and Depletion (2016 - 2025)

Thermo Fisher Scientific (TMO) has disclosed Depreciation and Depletion for 16 consecutive years, with $304.0 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Depreciation and Depletion rose 10.14% year-over-year to $304.0 million, compared with a TTM value of $1.2 billion through Dec 2024, up 8.15%, and an annual FY2025 reading of $1.0 billion, down 9.17% over the prior year.
  • Depreciation and Depletion was $304.0 million for Q4 2024 at Thermo Fisher Scientific, up from $290.0 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $304.0 million in Q4 2024 and bottomed at $149.0 million in Q1 2020.
  • Average Depreciation and Depletion over 5 years is $234.9 million, with a median of $247.0 million recorded in 2022.
  • The sharpest move saw Depreciation and Depletion skyrocketed 34.39% in 2021, then increased 1.2% in 2023.
  • Year by year, Depreciation and Depletion stood at $191.0 million in 2020, then grew by 13.61% to $217.0 million in 2021, then grew by 17.97% to $256.0 million in 2022, then grew by 7.81% to $276.0 million in 2023, then grew by 10.14% to $304.0 million in 2024.
  • Business Quant data shows Depreciation and Depletion for TMO at $304.0 million in Q4 2024, $290.0 million in Q3 2024, and $276.0 million in Q2 2024.